ChromaDex (NASDAQ:CDXC) Downgraded to “Buy” Rating by StockNews.com

StockNews.com cut shares of ChromaDex (NASDAQ:CDXC) from a strong-buy rating to a buy rating in a research report report published on Thursday.

Other research analysts have also recently issued research reports about the stock. Roth Mkm lifted their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. LADENBURG THALM/SH SH boosted their target price on shares of ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a research note on Wednesday.

ChromaDex Price Performance

NASDAQ CDXC opened at $7.69 on Thursday. The company has a market capitalization of $587.39 million, a PE ratio of 769.77 and a beta of 2.21. The company has a fifty day moving average of $5.72 and a 200 day moving average of $5.15. ChromaDex has a 1 year low of $1.57 and a 1 year high of $9.18.

Insider Activity at ChromaDex

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the company’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now owns 244,179 shares of the company’s stock, valued at approximately $1,511,468.01. This represents a 13.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 9.64% of the stock is owned by corporate insiders.

Institutional Trading of ChromaDex

Several large investors have recently bought and sold shares of CDXC. D. E. Shaw & Co. Inc. grew its stake in ChromaDex by 1,785.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company’s stock valued at $5,365,000 after acquiring an additional 957,665 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in ChromaDex by 288.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 662,956 shares of the company’s stock valued at $3,517,000 after purchasing an additional 492,148 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in ChromaDex by 189.0% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 506,186 shares of the company’s stock valued at $2,685,000 after purchasing an additional 331,014 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in ChromaDex in the 4th quarter valued at about $1,647,000. Finally, Renaissance Technologies LLC boosted its holdings in ChromaDex by 68.0% in the 4th quarter. Renaissance Technologies LLC now owns 712,788 shares of the company’s stock valued at $3,781,000 after purchasing an additional 288,588 shares during the last quarter. Hedge funds and other institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.